ATE549013T1 - Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren - Google Patents

Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren

Info

Publication number
ATE549013T1
ATE549013T1 AT10160099T AT10160099T ATE549013T1 AT E549013 T1 ATE549013 T1 AT E549013T1 AT 10160099 T AT10160099 T AT 10160099T AT 10160099 T AT10160099 T AT 10160099T AT E549013 T1 ATE549013 T1 AT E549013T1
Authority
AT
Austria
Prior art keywords
administration
reduced volume
glatiramer acetate
volume formulation
formulation
Prior art date
Application number
AT10160099T
Other languages
English (en)
Inventor
Ayelet Altman
Doris Saltkill
Dalton L Tomlinson
Tomer El-Gad
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42283140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE549013(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE549013T1 publication Critical patent/ATE549013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT10160099T 2009-07-15 2010-04-15 Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren ATE549013T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27100909P 2009-07-15 2009-07-15
US27134009P 2009-07-20 2009-07-20
US33701110P 2010-01-29 2010-01-29

Publications (1)

Publication Number Publication Date
ATE549013T1 true ATE549013T1 (de) 2012-03-15

Family

ID=42283140

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10160099T ATE549013T1 (de) 2009-07-15 2010-04-15 Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren

Country Status (20)

Country Link
US (3) US20110060279A1 (de)
EP (2) EP2275086B1 (de)
JP (1) JP2012533540A (de)
AR (1) AR077484A1 (de)
AT (1) ATE549013T1 (de)
AU (1) AU2010273234A1 (de)
BR (1) BR112012000878A2 (de)
CA (1) CA2697570C (de)
DK (1) DK2275086T3 (de)
EA (1) EA201270167A1 (de)
ES (1) ES2383347T3 (de)
HK (1) HK1152249A1 (de)
HR (1) HRP20120349T1 (de)
IL (1) IL217240A0 (de)
MX (1) MX2012000687A (de)
PL (1) PL2275086T3 (de)
PT (1) PT2275086E (de)
RS (1) RS52367B (de)
WO (1) WO2011008274A2 (de)
ZA (1) ZA201200586B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
EP2275086B1 (de) 2009-07-15 2012-03-14 Teva Pharmaceutical Industries, Ltd. Formulierung von Glatirameracetat mit verringertem Volumen und Verabreichungsverfahren
DK3199172T3 (en) 2009-08-20 2018-10-08 Yeda Res & Dev DOSAGE regimen for multiple sclerosis
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
AU2013305182B2 (en) * 2012-08-20 2017-01-12 Shl Medical Ag Automatic injection device
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
BR112015021780A2 (pt) * 2013-03-08 2017-07-18 Teva Pharmaceutical Industries Ltd dispositivo injetor reutilizável para seringa
MX2015011451A (es) * 2013-03-08 2016-06-10 Teva Pharma Dispositivo inyector reutilizable para jeringa.
US8591463B1 (en) * 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
UA119055C2 (uk) 2014-02-26 2019-04-25 Аллерган, Інк. Пристрій доставляння внутрішньоочного імплантата та способи його використання
US9415176B1 (en) 2015-01-22 2016-08-16 West Pharmaceutical Services, Inc. Autoinjector having an end-of-dose visual indicator
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CA3042493A1 (en) * 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN110996983A (zh) 2017-06-26 2020-04-10 巴斯德研究所 清除hiv储库并降低病毒载量的治疗
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2017924B3 (es) * 1985-10-11 1991-03-16 Duphar Int Res B V Inyector automatico.
NL8701091A (nl) * 1987-05-08 1988-12-01 Spruyt Hillen Bv Injectiepen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8926825D0 (en) * 1989-11-28 1990-01-17 Glaxo Group Ltd Device
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6454746B1 (en) * 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SE518981C2 (sv) * 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
CN100464796C (zh) * 2002-11-25 2009-03-04 特克法马许可公司 包括可复位安全释放设备的自动注射器
US7585843B2 (en) * 2003-10-03 2009-09-08 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2579038A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
ES2572811T3 (es) * 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
CN101044188B (zh) * 2004-10-29 2010-08-04 桑多斯股份公司 制备格拉太咪尔的方法
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070161960A1 (en) * 2006-01-12 2007-07-12 Fu-Yuan Li Lancet device
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
MX2008016335A (es) * 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
USD622374S1 (en) * 2006-09-06 2010-08-24 Abbott Biotechnology Ltd. Automatic injection device
WO2009070298A1 (en) * 2007-11-28 2009-06-04 Teva Pharmaceutical Industries, Ltd. Method of delaying the onset of clinically definite multiple sclerosis
USD607558S1 (en) * 2008-09-19 2010-01-05 Becton Dickinson France S.A.S. Medicine injector
EP2275086B1 (de) 2009-07-15 2012-03-14 Teva Pharmaceutical Industries, Ltd. Formulierung von Glatirameracetat mit verringertem Volumen und Verabreichungsverfahren

Also Published As

Publication number Publication date
WO2011008274A2 (en) 2011-01-20
EP2275086B1 (de) 2012-03-14
PL2275086T3 (pl) 2012-09-28
US20110060279A1 (en) 2011-03-10
AU2010273234A1 (en) 2012-02-23
DK2275086T3 (da) 2012-07-09
WO2011008274A3 (en) 2011-09-22
CA2697570C (en) 2011-11-01
AR077484A1 (es) 2011-08-31
EP2453907A2 (de) 2012-05-23
EA201270167A1 (ru) 2012-08-30
HRP20120349T1 (hr) 2012-07-31
US20110066112A1 (en) 2011-03-17
BR112012000878A2 (pt) 2019-09-24
ES2383347T3 (es) 2012-06-20
EP2275086A1 (de) 2011-01-19
IL217240A0 (en) 2012-02-29
CA2697570A1 (en) 2010-06-22
RS52367B (en) 2012-12-31
US9018170B2 (en) 2015-04-28
HK1152249A1 (en) 2012-02-24
JP2012533540A (ja) 2012-12-27
ZA201200586B (en) 2013-10-30
PT2275086E (pt) 2012-05-18
MX2012000687A (es) 2012-09-07
WO2011008274A4 (en) 2011-11-10
US7855176B1 (en) 2010-12-21

Similar Documents

Publication Publication Date Title
ATE549013T1 (de) Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
HK1250313A1 (zh) 穩定的藥物組合物和使用所述組合物的方法
ES2618221T8 (es) Dispositivo de administración de prótesis vascular y método de uso
SMT201600194B (it) Composizione e formulazione comprendente iduronato-2-s0lfatasi umano ricombinante e suo metodo di preparazione
EP2555751A4 (de) Medizinische vorrichtungen mit medikamenten sowie verfahren zu ihrer herstellung und verwendung
BR112015011111A2 (pt) proteína multifuncional e formulação farmacêutica
DK2493531T4 (da) Lægemiddelfremføringsindretninger og fremgangsmåde til samling
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
DK2529756T3 (da) Risperidon- og/eller paliperidon-implantatformulering
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
IL254446A0 (en) Implantable drug delivery preparations and treatment methods thereof
EP2471541A4 (de) Medizin zur auflösung und entfernung von warzen und wucherungen aus proteinen und ihre anwendung
ZA201502695B (en) Stable pharmaceutical composition of peginterferon alpha-2b
BR112013034066A2 (pt) método de administração e tratamento
HK1211594A1 (en) Human relaxin analogue, pharmaceutical composition of same, and pharmaceutical application of same
HK1198910A1 (en) Pharmaceutical composition comprising ebastine and fluticasone
IL221535A (en) Cyclic tetrapeptides and their therapeutic applications
HUP1000407A2 (en) Ph dependent pulsatile and sustained release pharmaceutical composition
SI2275086T1 (sl) Formulacija glatiramer acetata z zmanjšanim volumnom in postopki za dajanje
EP2640468A4 (de) Verabreichungs- und behandlungsverfahren
BRPI1009313A2 (pt) preparação farmacêutica transdérmica e administração de tirofiban
BR112013004180A2 (pt) composição fotoprotetora e uso da composição
FR2969606B1 (fr) Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
TH1301001450B (th) สูตรผสมสำหรับแกรนูโลไซต์โคโลนีสติมูเลติงแฟกเตอร์ของวัวและสิ่งแปรผันของมัน